Journal profile · ONCOLOGY
JMIR Cancer
ISSN 2369-1999 · JMIR Publications · Canada
JMIR Cancer: CAS Zone 3 · Medicine (2025 upgraded edition); impact factor 2.6 (journal website); fully open access; APC about USD 1,985; median 163 days to acceptance (101 articles, last 24 months); 152 articles in 2025; indexed in ESCI and Scopus.
Scope
Aims, scope and focus
JMIR Cancer is published by JMIR Publications and is in Zone 3 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Cancer survivorship and care, Mobile Health and mHealth Applications and Health Literacy and Information Accessibility, together about 41% of its articles. (generated from OpenAlex topic counts and CAS ranking data)
JMIR Cancer (JC, ISSN: 2369-1999) is a peer-reviewed journal focusing on education, innovation and technology in cancer care, cancer survivorship and cancer research, and participatory and patient-centred approaches. This journal also includes research on non-Internet approaches to improve cancer care and cancer research. JMIR Cancer is indexed in PubMed Central and PubMed, Scopus, DOAJ, CINAHL, MEDLINE, and the Emerging Sources Citation Index (Clarivate). We invite submissions of original research, viewpoints, reviews, tutorials, case studies, and non-conventional articles (e.g. open patient education material and software resources that are not yet evaluated but are free for others to use/implement). In our "Patients' Corner," we invite patients and survivors to submit short essays and viewpoints on all aspects of cancer. In particular, we are interested in suggestions on improving the health care system and suggestions for new technologies, applications and approaches (this section has no article processing fees). In case of acceptance, an Article Processing Fee will be charged to cover copyediting and typesetting costs (see fee schedule). Need help choosing a journal? Use our Journal Finder tool to find the perfect match for your manuscript. Get Started
From the journal's Aims & Scope
Research area (LetPub): ONCOLOGY
Editor-in-chief Proposals Theme IssuesPublisher website
Editorial board by country: none in mainland China; most named United States 7, Canada 3, Singapore 1 (11 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Cancer survivorship and careMedicine24.4%
- Mobile Health and mHealth ApplicationsHealth Professions9.1%
- Health Literacy and Information AccessibilityHealth Professions7.5%
- Digital Mental Health InterventionsPsychology6%
- Global Cancer Incidence and ScreeningMedicine5.3%
- Social Media in Health EducationSocial Sciences5.3%
- Childhood Cancer Survivors' Quality of LifeMedicine4.2%
- Cancer-related cognitive impairment studiesMedicine3.8%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Oncology | Zone 3 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Oncology | Zone 3 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Not covered
Not covered by this edition.
Database indexing
ESCIScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
MEDLINEPMCCINAHLPublisher website
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor (publisher) 2025
- 2.6Publisher website ·
- CiteScore 2026-06
- 4.1LetPub ·
- CiteScore (publisher) 2025
- 4.1Publisher website ·
- SJR 2026-06
- 0.8LetPub ·
- SNIP 2026-06
- 0.94LetPub ·
- h-index
- 42OpenAlex ·
- i10-index
- 256OpenAlex ·
- 2-year mean citedness
- 3.63OpenAlex ·
- Self-citation rate
- 7.7%LetPub ·
- Share of gold OA articles
- 98.86%LetPub ·
Volume
- Articles per year
- 145LetPub ·
Articles by year OpenAlex count · 664 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 97 | 97 | 35 |
| 2025 | 152 | 152 | 686 |
| 2024 | 77 | 77 | 463 |
| 2023 | 59 | 59 | 586 |
| 2022 | 80 | 80 | 1,199 |
| 2021 | 63 | 63 | 1,935 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
163 daysMedian, submission to acceptance · P25–P75 117 days – 248 days
- Acceptance to online
- median 46 days (101 articles)
- Submission to online
- median 217 days
- Sample
- 101 articles with submission and acceptance dates (275 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 12 weeksLetPub ·
- Submission to publication (journal-reported)
- about 18 weeksDOAJ ·
- Peer review
- Single anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessDOAJ
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | USD 1,985 | Yes | CC BY | |
| OpenAlex | USD 1,873 | — | — | |
| LetPub | USD 1,985 | Yes | — | |
| Publisher website | No APC | — | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
What to prepare2 items from the author guidelines
- Reference style
- AMA
- Cover letter
- Required
Policy excerpts from the journal's websiteAuthorship, Peer review, Preprints
- Authorship
ORCID required for all authors at time of publication Model summary
JMIR Publications requires that all authors / coauthors have an ORCID (a unique researcher identifier) at the time of publication.
Source ↗Publisher website ·- Peer review Preprints Open for Peer Review
No prior publication or simultaneous submission Model summary
2026-09-04 | Share on Bluesky Share on Twitter Share on Facebook Share on LinkedIn What matters most? Qualitative insights into factors impacting quality of life in people living with or beyond cancer across Europe Open Peer Review Period: September 08, 2026 - November 03, 2026 Peer Review Me 2026-08-28 | Share on Bluesky Share on Twitter Share on Facebook Share on LinkedIn Evaluating Person-Centr…
Source ↗Publisher website ·- Preprints Preprints Open for Peer Review
2026-09-04 | Share on Bluesky Share on Twitter Share on Facebook Share on LinkedIn What matters most? Qualitative insights into factors impacting quality of life in people living with or beyond cancer across Europe Open Peer Review Period: September 08, 2026 - November 03, 2026 Peer Review Me 2026-08-28 | Share on Bluesky Share on Twitter Share on Facebook Share on LinkedIn Evaluating Person-Centr…
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- JMIR Publications
- Country or region
- Canada
- Language
- English
- ISSN
- 2369-1999
- Official links
- Journal homepage ↗LetPub
- Author guidelines ↗LetPub
- Aims & Scope ↗LetPub
- APC information ↗DOAJ
- Fee waivers ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗LetPub
- Editorial board ↗LetPub
FAQ
Frequently asked questions about JMIR Cancer
What CAS zone is JMIR Cancer in?
In the 2025 upgraded edition of the CAS Journal Ranking, JMIR Cancer is in Zone 3 of Medicine, and in Zone 3 of the minor category Oncology. In the 2026 Xinrui edition it is in Zone 3 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of JMIR Cancer?
The journal's website gives an impact factor of 2.6 (2025); this is the journal's own figure, as LetPub lists none for it; CiteScore 4.1, h-index 42.
How long does peer review take at JMIR Cancer?
Based on the dates recorded on 101 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 163 days (interquartile range 117–248 days); authors report an average review time of about 12 weeks. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What are the manuscript requirements of JMIR Cancer?
According to the journal's author guidelines: Reference style: AMA; Cover letter: Required. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.
Where are the editorial board members of JMIR Cancer based?
Of the 11 board members whose country the journal's board page names, none are in mainland China; the countries named most often are United States (7), Canada (3) and Singapore (1). Counted from the institutions listed on the board page; for reference only.
Which databases index JMIR Cancer?
According to LetPub and DOAJ records, JMIR Cancer is indexed in ESCI, Scopus and DOAJ. The journal's website also lists MEDLINE, PMC and CINAHL; that list has not been checked against each database.
Is JMIR Cancer open access, and what is the APC?
JMIR Cancer is a fully open-access journal. APC about USD 1,985.
Sources and updates
The facts on this page come from LetPub, OpenAlex, DOAJ, Publisher website; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .